BeyondSpring (BYSI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for September 15, 2025, at 9:00 AM ET at 100 Campus Drive, Florham Park, NJ.
Shareholders can vote in person or electronically using a 12-digit control number.
Proxy materials, including the proxy statement and card, are available online for review and download.
Voting matters and shareholder proposals
Proposal to ratify the appointment of CBIZ CPAS P.C. as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends a vote "FOR" the ratification of the auditor.
Other matters may be addressed as properly brought before the meeting or any adjournment.
Audit committee and external auditor matters
Ratification of CBIZ CPAS P.C. as the independent auditor for the upcoming fiscal year is up for shareholder vote.
Latest events from BeyondSpring
- Net loss increased to $5.7M in Q2 2026, with urgent need for new funding amid ongoing R&D.BYSI
Q2 2026 - Plinabulin and SEED's TPD platform offer transformative potential for cancer care and beyond.BYSI
Corporate presentation - Q1 2026 net loss was $6.7M, cash at $7.9M, and Plinabulin advanced as an ADC agent.BYSI
Q1 2026 - Plinabulin achieved Phase 3 survival benefit in NSCLC; financials strengthened and pipeline advanced.BYSI
Q4 2025 - Biopharma firm registers 10M shares for R&D and corporate use, facing clinical and financial risks.BYSI
Registration Filing - Up to 10M shares registered for flexible sale to fund R&D amid ongoing financial uncertainty.BYSI
Registration Filing - Shareholders will vote to ratify CBIZ as auditor at the September 2025 AGM.BYSI
Proxy Filing - Net loss narrowed, Plinabulin advanced in NSCLC, SEED divested and raised $30M, cash at $12.5M.BYSI
Q3 2025 - Q2 2025 saw narrowed net loss, SEED divestiture progress, and clinical advances in oncology.BYSI
Q2 2025